PRESS RELEASES

Year
January 20 | 2026
GSK enters agreement to acquire RAPT Therapeutics
January 07 | 2026
RAPT Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
November 06 | 2025
RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
November 04 | 2025
RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences
October 27 | 2025
RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies
October 21 | 2025
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
October 21 | 2025
RAPT Therapeutics Announces Proposed Public Offering of Common Stock
October 20 | 2025
RAPT Therapeutics and Shanghai Jeyou Pharmaceutical Announce Positive Topline Data from Phase 2 Trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria
October 19 | 2025
RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)
September 29 | 2025
RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy